This study employed peptide microarray technology (Carmona 2015) to identify highly specific linear B-cell epitopes of the SARS-CoV-2 Spike protein that can distinguish between SARS-CoV-2 infection and pre-existing immunity to seasonal coronaviruses.

Biotome is pleased to announce the arrival of our first prototype diagnostic test kits from manufacturing partner Biosensis Pty Ltd. These kits represent the culmination of years of research into precision detection of high-virulence Helicobacter pylori strains that significantly elevate gastric cancer risk.

Perth, Western Australia - July 2, 2024: - Biotome Pty Ltd , a Western Australian biotechnology company, has been awarded an Innovation Booster Grant from the Western Australian Government's New Industries Fund . This grant will support the development and international patenting of Biotome's innovative preeclampsia risk test. The test, which uses novel peptide targets to detect specific antibodies in the blood, aims to provide early risk assessment for preeclampsia, a condi

Thursday, August 25th, 2022 - Perth, Australia: Biotome has been granted US Patent No. 11,401,308 covering the use of peptides that can detect CagA+ Helicobacter pylori infection for use in diagnostics. Diagnostics using these peptides can identify individuals with carcinogenic CagA+ H. pylori infection, which is a major risk factor for developing stomach cancer. The patented peptides offer significant advantages over existing antigen-based methods as they target specific a

Tuesday, July 5th, 2022 - Perth, Australia: Biotome has been awarded $497,000 in funding from the Western Australian Future Health Research & Innovation Fund , to develop their precision diagnostic for stomach cancer risk. This test will be the world’s first diagnostic for stomach cancer risk with high enough accuracy and a low enough cost to be used for public health screening. It has the potential to save thousands of lives in Australia, and millions around the world. Biot

Perth, Australia – May 4, 2021 - Precision diagnostics company Biotome Pty Ltd has entered into a technology partnership with Cardea Bio Inc , a global leader in nanoelectronics manufacturing and the only mass-producer of graphene-based biological transistors. Through Biotome joining Cardea’s Innovation Partnership Program, the companies can work together to leverage Cardea’s proprietary Cardean Transistor™ technology for the development of electrochemical biosensors for pr